BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sümbül AT, Akkız H, Bayram S, Bekar A, Akgöllü E, Sandıkçı M. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep. 2012;39:1639-1647. [PMID: 21607615 DOI: 10.1007/s11033-011-0903-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Ding C, Yu H, Yu H, Qin H. TP53 codon 72 polymorphism with hepatocellular carcinoma: a metaanalysis. J Int Med Res 2012;40:446-54. [PMID: 22613405 DOI: 10.1177/147323001204000206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases. Meta Gene 2013;1:126-37. [PMID: 25606382 DOI: 10.1016/j.mgene.2013.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Jia S, Tang W, Luo Y. p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis. Hepatol Int 2013;7:669-75. [PMID: 26201800 DOI: 10.1007/s12072-012-9389-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Duan X, Li J. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis. Medicine (Baltimore) 2017;96:e7856. [PMID: 28885338 DOI: 10.1097/MD.0000000000007856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
5 Eskander EF, Abd-Rabou AA, Mohamed MS, Yahya SM, El Sherbini A, Shaker OG. The potential impact of P53 and APO-1 genetic polymorphisms on hepatitis C genotype 4a susceptibility. Gene 2014;550:40-5. [PMID: 25108128 DOI: 10.1016/j.gene.2014.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biol 2014;35:3647-56. [PMID: 24326769 DOI: 10.1007/s13277-013-1483-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Cai J, Cai Y, Ma Q, Chang F, Xu L, Zhang G, Guo X. Association of p53 codon 72 polymorphism with susceptibility to hepatocellular carcinoma in a Chinese population from northeast Sichuan. Biomed Rep 2017;6:217-22. [PMID: 28357076 DOI: 10.3892/br.2017.840] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Li G, Feng B, Deng YC, Li DS, Julaiti·Ainiwaer, Zhang LW. Construction and identification of recombinant adenovirus expression vectors expressing short hairpin RNAs targeting HPV18 E6 and E7Shijie Huaren Xiaohua Zazhi 2014; 22(24): 3608-3612 [DOI: 10.11569/wcjd.v22.i24.3608] [Reference Citation Analysis]
9 Zhang Q, Ma YY, Wang HJ, Shao CM, Zhang J, Ye ZY. Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer. J Surg Oncol. 2013;107:360-366. [PMID: 22886602 DOI: 10.1002/jso.23233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
10 Mancini F, Giorgini L, Teveroni E, Pontecorvi A, Moretti F. Role of Sex in the Therapeutic Targeting of p53 Circuitry. Front Oncol 2021;11:698946. [PMID: 34307167 DOI: 10.3389/fonc.2021.698946] [Reference Citation Analysis]
11 Wungu CDK, Amin M, Ruslan SEN, Purwono PB, Kholili U, Maimunah U, Setiawan PB, Lusida MI, Soetjipto S, Handajani R. Association between host TNF-α, TGF-β1, p53 polymorphisms, HBV X gene mutation, HBV viral load and the progression of HBV-associated chronic liver disease in Indonesian patients. Biomed Rep 2019;11:145-53. [PMID: 31565220 DOI: 10.3892/br.2019.1239] [Reference Citation Analysis]
12 Bayram S, Rencüzoğulları E, Almas AM, Genç A. Effect of p53 Arg72Pro polymorphism on the induction of micronucleus by aflatoxin B1 in in vitro in human blood lymphocytes. Drug and Chemical Toxicology 2016;39:331-7. [DOI: 10.3109/01480545.2015.1121275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, Bharadwaj M. Association of MDM2 and p53 Polymorphisms with the Advancement of Cervical Carcinoma. DNA and Cell Biology 2013;32:19-27. [DOI: 10.1089/dna.2012.1718] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
14 Li Y, Wang K, Dai L, Wang P, Song C, Shi J, Ren P, Ye H, Zhang J. HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility. Oncol Lett 2012;4:358-64. [PMID: 22844383 DOI: 10.3892/ol.2012.728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Yuan F, Zhang LS, Li HY, Liao M, Lv M, Zhang C. Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China. DNA Cell Biol 2013;32:268-73. [PMID: 23570557 DOI: 10.1089/dna.2012.1910] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
16 Khan MH, Khalil A, Rashid H. Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis. Genet Res (Camb) 2015;97:e7. [PMID: 25882871 DOI: 10.1017/S0016672315000075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
17 Koutb F, Abdel-Rahman S, Hassona E, Haggag A. Association of C-myc and p53 Gene Expression and Polymorphisms with Hepatitis C (HCV) Chronic Infection, Cirrhosis and Hepatocellular Carcinoma (HCC) Stages in Egypt. Asian Pac J Cancer Prev 2017;18:2049-57. [PMID: 28843220 DOI: 10.22034/APJCP.2017.18.8.2049] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Deng X, Liang J, Jiang M, Zhou X, Liu H. Association between the C.1161G>A and C.1779C>G genetic variants of XRCC1 gene and hepatocellular carcinoma risk in Chinese population. Int J Biol Sci 2013;9:289-94. [PMID: 23493666 DOI: 10.7150/ijbs.5928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Qiu M, Liu Y, Yu X, Qin L, Bei C, Zeng X, Qiu X, Tang B, He S, Yu H. Interaction between p53 codon 72 and MDM2 309T& gt; G polymorphisms and the risk of hepatocellular carcinoma. Tumour Biol. 2016;37:3863-3870. [PMID: 26476535 DOI: 10.1007/s13277-015-4222-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
20 Peng Q, Lao X, Chen Z, Lai H, Deng Y, Wang J, Mo C, Sui J, Wu J, Zhai L. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2013;8:e82773. [PMID: 24376578 DOI: 10.1371/journal.pone.0082773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
21 Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol 2013;34:1451-9. [PMID: 23564481 DOI: 10.1007/s13277-013-0649-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]